About Dyno Therapeutics
Dyno Therapeutics is a biotechnology company that applies artificial intelligence and high-throughput in vivo experimentation to engineer Adeno-Associated Virus (AAV) capsid vectors for gene therapy delivery. Its proprietary CapsidMap platform discovers and optimizes AAV capsids that outperform current approaches, expanding the range of diseases treatable with gene therapies. The company serves biopharmaceutical partners by providing advanced AAV vectors targeting tissues such as the CNS, eye, liver, and muscle.
Company details
Funding
Total raised
$109M
Last stage
Series A
Investors
Founders
Eric Kelsic
Founder and CEO of Dyno Therapeutics; previously a researcher at the Wyss Institute at Harvard. Pioneered AI/ML approaches to AAV capsid engineering.
LinkedInAdrian Veres
Co-Founder and CSO at Dyno Therapeutics; holds degrees from Harvard University in Chemistry and Physics.
Alan Crane
Entrepreneur Partner at Polaris Partners; previously President and CEO of Momenta Pharmaceuticals.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.